Melatonin night shift workers may gain a new tool against cancer risk: a first-of-its-kind trial found that 3 mg before ...

The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with ...

Radical prostatectomy is potentially curative in patients with high-risk localized or locally advanced prostate cancer; however, relapse occurs within 5 years in up to 50% of patients. We ...

Johnson & Johnson’s PROTEUS Phase 3 trial shows apalutamide + hormone therapy before/after surgery improves outcomes in ...

Treatment regimen cut disease recurrence or death risk by 20% Researchers call data 'paradigm changing' J&J plans to seek expanded approvals for Erleada May 31 (Reuters) - Johnson & Johnson's (JNJ.N), ...

Thousands of men with advanced prostate cancer could soon live longer thanks to a treatment which cuts the risk of the ...

With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap. For patients with high-risk localized or locally advanced ...

(UroToday.com) The 2026 SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Bryce Tan discussing a study assessing the efficacy of immunological priming of ...

A previous trial involving patients with metastatic prostate cancer that was resistant to androgen pathway modulation (formerly referred to as castration-resistant) showed that adding talazoparib ...

Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer.  | After winning a broader FDA label in metastatic castration-resistant prostate cancer, ...

Japanese medical device company Olympus Corporation announced today it has signed a definitive agreement to acquire Israeli ...

Olympus Corporation (Olympus), a global MedTech company committed to advancing endoscopy-enabled care, announced today it has signed a definitive agreement to acquire BioProtect Ltd. (BioProtect), a ...